Applied Clinical Trials-02-01-2005

View from Washington
Applied Clinical Trials

February 01, 2005

Concerns over risky medicines are shutting down clinical studies and boosting demand for comparative drug analysis.

Technology Viewpoint
Applied Clinical Trials

February 01, 2005

Writing computer code isn?t as difficult as you might think.

Applied Clinical Trials
Feature Article

February 01, 2005

Because it can take time to obtain independent EC or review board approval, the temptation to start a study without it can become strong.

Letters to the Editor
Applied Clinical Trials

February 01, 2005

Readers respond to articles and commentaries.

Applied Clinical Trials
A Closing Thought

February 01, 2005

In the biomedical research industry, and at Pfizer in particular, we are committed to what we call "The Three As"-making medicines available, accessible, and affordable.

View from Brussels
Applied Clinical Trials

February 01, 2005

Industry?s proposal for a shared database has merit, but is it ?too little too late??

Applied Clinical Trials

If the activity is a significant risk device study, surgeons must first obtain FDA and IRB approval.

Applied Clinical Trials
Guest Editorial

February 01, 2005

Perhaps a way forward is to refocus our efforts on a "culture of conscience," since our conscience often guides our actions.

Applied Clinical Trials
Feature Article

February 01, 2005

Our training places heavy emphasis on site selection: The entire study may suffer if sites are chosen poorly.

Applied Clinical Trials
eShowcase

February 01, 2005

A new database design is behind a way of generating reports when you want them--such as right now

Applied Clinical Trials
Feature Article

February 01, 2005

Most pharmaceutical companies place a high priority on reducing their costs to offset pressure on profit margins. They also struggle to accelerate the development of profitable new drugs: Based on drug sale statistics, pharmaceutical companies lose substantial revenue each day a new drug is delayed from reaching the market.